☆ 4.7 Letter

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer

ANNALS OF ONCOLOGY (2021)

Get Full Text
Add to Collection

Journal

ANNALS OF ONCOLOGY
Volume 32, Issue 6, Pages 817-819

Publisher

ELSEVIER
DOI: 10.1016/j.annonc.2021.02.010

Keywords

-

Categories

Oncology

Funding

  1. Loxo Oncology
  2. National Institutes of Health (NIH) [R01CA242845]
  3. Oklahoma Tobacco Settlement Endowment Trust
  4. Cancer Prevention and Research Institute of Texas [RP1100584]
  5. Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy [1U01 CA180964]
  6. NCATS Grant [UL1 TR000371]
  7. MD Anderson Cancer Center Support Grant [P30 CA016672]
  8. NIH/National Institute of General Medical Sciences [P20GM103639]
  9. NIH/National Cancer Institute [P30CA225520]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.